# Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection

> **NCT02688790** · PHASE1 · TERMINATED · sponsor: **AbbVie** · enrollment: 8 (actual)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** Dalbavancin

## Key facts

- **NCT ID:** NCT02688790
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04-01
- **Primary completion:** 2019-04-03
- **Final completion:** 2019-04-03
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2022-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02688790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02688790, "Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02688790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*